Vireo Growth (VREOF) Accumulated Expenses (2020 - 2026)
Vireo Growth (VREOF) posted Accumulated Expenses of $33.3 million for Q1 2026, up 25.19% sequentially from $26.6 million in Q4 2025, and up 667.11% YoY from $4.3 million in Q1 2025.
Vireo Growth (VREOF) Accumulated Expenses (2020 - 2026) Analysis & Trends
Vireo Growth has reported Accumulated Expenses for 7 years, with the latest figure at $33.3 million in Q1 2026.
- Quarterly Accumulated Expenses rose 667.11% year-over-year to $33.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.3 million (up 667.11% YoY) and the FY2025 annual result came in at $26.6 million, up 288.9% from the prior year.
- Accumulated Expenses climbed to $33.3 million in Q1 2026 per VREOF's latest filing, from $26.6 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $33.3 million in Q1 2026 and troughed at $4.3 million in Q3 2024.
- A 5-year average of $11.4 million and a median of $7.4 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses tumbled 77.14% in 2024, then surged 667.11% in 2026.
- Over 5 years, Accumulated Expenses stood at $6.2 million in 2022, then slipped by 21.39% to $4.9 million in 2023, then surged by 40.95% to $6.8 million in 2024, then jumped by 288.9% to $26.6 million in 2025, then increased by 25.19% to $33.3 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $33.3 million, $26.6 million, and $17.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.30 Mn |
| Dec 31, 2025 | 26.60 Mn |
| Sep 30, 2025 | 17.76 Mn |
| Jun 30, 2025 | 17.39 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Dec 31, 2024 | 6.84 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 4.63 Mn |
| Dec 31, 2023 | 4.85 Mn |
| Sep 30, 2023 | 18.80 Mn |
| Jun 30, 2023 | 15.73 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.37 Mn |
| Jun 30, 2022 | 7.91 Mn |
| Mar 31, 2022 | 7.62 Mn |
| Dec 31, 2021 | 7.71 Mn |
| Sep 30, 2021 | 3.62 Mn |
| Jun 30, 2021 | 5.61 Mn |